Royalty Report: Drugs, Disease, Therapeutic – Collection: 248373

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Diagnostic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 248373

License Grant
For the Development License, Licensor grants the Belgian Licensee a co-exclusive, with Licensor, right and license under Licensor Patent Rights and Licensors rights under Joint Patent Rights, to Develop Product Candidates and Products in the Territory in the Field.

For the Commercialization License, Licensor grants an exclusive right and license under Licensor Patent Rights and Licensors rights under Joint Patent Rights, to Commercialize Product Candidates and Products in the Territory in the Field.

For the Know-How License, Licensor grants an exclusive license in the Field in the Territory under all Licensor Know-How to the extent that it relates exclusively to Compounds, Product Candidates or Products, solely to discharge Licensees obligations and exercise its rights under this Agreement.

For the Manufacturing License, Licensor grants an exclusive license in the Field in the Territory to Manufacture Product Candidates and Products for Commercial use in the Territory, and a co-exclusive,  with Licensor, right and license to Manufacture Product Candidates and Products for purposes of exercising its rights under the Development License, in each case under Licensor Patent Rights, Licensor Know-How and Licensors right under Joint Patent Rights.

For the License of Trademarks, prior to Commercialization of a Product, the Parties shall enter into a trademark licensing agreement to use logos chosen and owned by Licensor and the Trademarks Controlled by Licensor, on labeling, package inserts, monographs and packaging materials for the Product, Product Materials and samples, and other materials used in connection with the performance of this Agreement during its term.

License Property
Licensor is developing VX-950, a novel inhibitor of the NS3/4A hepatitis C viral protease.

Compound means VX-950, or any Backup Compound that is included in this Agreement, and all of its or their prodrugs and metabolites, its or their stereoisomers and tautomers, and all of the esters, salts, hydrates, solvates, inclusion complexes and polymorphs of any of the foregoing.

Product means any pharmaceutical preparation in final commercial form containing the Product Candidate, for sale by prescription, over-the-counter or any other method. Product includes without limitation any Combination Product.

Product Candidate means a pharmaceutical composition containing a Compound as an active ingredient.

The property includes US patent application 10/344,112 and related applications.

Field of Use
Field means all human and animal therapeutic and/or prophylactic uses of Product Candidates and Products.

VX-950 is an investigational oral inhibitor of hepatitis C virus protease, an enzyme essential for viral replication, and is one of the most advanced investigational agents that specifically targets HCV. In clinical studies to date, researchers have observed rapid and dramatic antiviral activity with VX-950.

IPSCIO Record ID: 253919

License Grant
The Parties have developed telaprevir and Belgian Licensee has commercialized Incivo (telaprevir) in the Territory under the terms of the Parent Agreement, and the Parties each now wish to further amend the rights and obligations of the Parties under the Parent Agreement and the Website Cooperation Agreement.

The Parent Agreement shall terminate in its entirety as of the Amendment Effective Date.

With this Additional Development License , the Licensor grants a non-exclusive right and license under the Licensor Know-How, Patent Rights and Licensors rights under Joint Patent Rights to Develop and Manufacture VX-950 and Products containing VX-950 in North America.

License Property
VX-950 is a novel inhibitor of the NS3/4A hepatitis C viral protease.

Compound means VX-950, or any Backup Compound that is included in this Agreement, and all of its or their prodrugs and metabolites, its or their stereoisomers and tautomers, and all of the esters, salts, hydrates, solvates, inclusion complexes and polymorphs of any of the foregoing.

Field of Use
The field of use is for hepatitis C.

IPSCIO Record ID: 209534

License Grant
For Licensed Products,  Licensor grants the Swiss Licensee an exclusive, even as to Licensor, license under the Licensor Patent Rights and Know-How, with the right to grant sublicenses, to make, use, sell, offer for sale, import and export Licensed Products for all uses in the Territory.

For HCV Activity Compounds, Licensor grants an exclusive, even as to Licensor, license under the Licensor Patent Rights to make, use, offer for sale, import and export any HCV Activity Compounds solely within the Field in the Territory.

Licensor grants a non-exclusive license under any such patents to develop, make, have made, import, export, use, offer for sale and sell Licensed Products for all uses in the Territory.

For research, Licensor grants a non-exclusive license under its patents, trademarks and other intellectual property only to the extent necessary to carry out Licensees obligations and responsibilities under the Research Program and to develop and commercialize a Licensed Product.

Licensee, its Affiliates and sublicensees shall be free to use and to register in any trademark office worldwide any Trademark for use with Licensed Products they desire in their sole discretion.

License Property
The Licensed Product means anything containing or derived from a Candidate Compound.  The Candidate Compound means chemical entities designed or identified by Licensor as of the Effective Date or pursuant to the Research Program that are inhibitors of at least one (1) protease of the Hepatitis C virus.

HCV Activity Compounds means Candidate Compounds, other than Licensed Products or Back-Up Compounds, or Non-Collaboration Compounds meeting the HCV Activity Criteria set forth.

The patents are those filed to protect Licensor Inventions or interest in Joint Inventions, or otherwise filed to protect either a transition state-based inhibitor of the NS3 protease of the Hepatitis C virus existing within Licensor Know-How as of the Effective Date or an inhibitor of the Hepatitis C viral proteases within Licensor KnowHow arising from the Research Program.

Field of Use
This agreement is for the treatment or prevention of Hepatitis C infections in humans and/or animals.

IPSCIO Record ID: 203459

License Grant
Licensor grants an exclusive, even as to Licensor, license, with the right to sublicense, under Licensors interest in Collaboration Patents, and Collaboration Know-How, in each case solely to develop, make, have made, use, sell, have sold, offer for sale and import Products in the Field in the Territory; provided, however, that Licensor retains such rights under Collaboration Technology as are necessary to perform its obligations under the Research Program.

This agreement also includes Non-Exclusive Cross-Licenses where each Party hereby grants to the other Party a non-exclusive, royalty-free license, without the right to sub-license:
(i) under such Partys interest in Collaboration Know-How for the manufacture or formulation of products other than Products, including 'cocktail' and other Combination Products; and
(ii) under such Partys interest in Collaboration Know-How, solely to conduct research in the HCV Field in the Territory.

License Property
Licensor has a research program for the discovery and optimization of nucleoside inhibitors of the NS5b polymerase in hepatitis C virus.

The Collaboration Compound shall mean a Nucleoside that satisfies the chemical and technical requirements set forth, and its Related Compounds and which:
(a) is or was synthesized by or for Licensor on or before the Effective Date or during the Research Program Term; or
(b) is a Related Compound to a Collaboration Compound disclosed by Licensor to Licensee pursuant to Identification and Contribution of Collaboration Compounds and which is synthesized by or for Licensee after the Effective Date.

The Collaboration Compound Products shall mean any preparations in final form, bulk form or other form containing as an active pharmaceutical ingredient one or more Selected Compounds.

Field of Use
The Field shall mean all human and animal therapeutic, diagnostic, and prophylactic uses, including, without limitation, the treatment, prevention and prophylaxis of hepatitis C viral infections.

The HCV Field shall mean the treatment of chronic hepatitis C viral infections in humans.

The Collaboration Compound Products are for sale by prescription, over-the-counter or any other method, including without limitation any Combination Product.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.